No Data
50 billion Honghu Fund's new move: buy shares of Inner Mongolia Yili Industrial Group and Shaanxi Coal Industry, targeting high-quality large cap blue chip stocks.
China Life Insurance and New China Life Insurance jointly initiated the establishment of the 50 billion Honghu Fund, which appeared in the top ten shareholders list of Inner Mongolia Yili Industrial Group and Shaanxi Coal Industry, with shareholding ratios of 1.88% and 0.72% respectively. In terms of investment, Honghu Fund prefers to invest in high-quality large market cap blue chip stocks, especially stocks with high dividend yields.
Lack of consumer willingness, china tourism group duty free corporation's performance continues to decline. Net profit in Q3 decreased by 50% year-on-year. interpretations
1. China Tourism Group Duty Free Corporation's Q3 quarterly net income attributable to parent company decreased by over fifty percent year-on-year, with insufficient consumer consumption willingness as the main reason for the decline; 2. Industry insiders said that various tax-free consumption indicators may continue to decline slowly in the short term.
Kweichow Moutai's performance in the first three quarters meets expectations. The timing for interim dividends and buybacks has not been determined yet. | Interpretations
①Kweichow Moutai's third-quarter earnings announced tonight basically meet expectations, with revenue growth exceeding the annual guidance; ②The proportion of direct sales in the first three quarters of this year has declined, which is related to the poor performance of the company's direct sales platform "i Moutai". In the first three quarters, i Moutai achieved a tax-free revenue of 14.766 billion yuan for alcoholic beverages, a slight decrease compared to the same period last year; ③Against the backdrop of current consumer softness, it is highly anticipated whether Kweichow Moutai will lower its operation targets next year.
Jiangsu Hengrui Pharmaceuticals' Q3 revenue was 6.59 billion yuan, with a net income of 1.19 billion yuan, a slight year-on-year increase of 1.9%. | Financial Report Watch
In the third quarter, jiangsu hengrui pharmaceuticals' eps was 0.19 RMB, a year-on-year increase of 5.56%. In the first three quarters, jiangsu hengrui pharmaceuticals' profit increased by 32.98% year-on-year, with eps increasing by 32.73% year-on-year. The main reason is that the company recognized the upfront payment received from Merck Healthcare of 0.16 billion euros as revenue, which significantly increased the profit.
"Pharmaceuticals king" for financing or listing in Hong Kong? Jiangsu Hengrui Pharmaceuticals has no comment on the rumors.
①There were reports last night that jiangsu hengrui pharmaceuticals is considering a secondary listing in Hong Kong next year, with an expected fundraising amount of 2 billion US dollars. In response, jiangsu hengrui pharmaceuticals stated that they have no comments; ② Industry insiders believe that a secondary listing in Hong Kong can not only raise funds but also enhance the company's international influence.
Nine joint-stock banks have followed suit today, with seven banks including Everbright and Guangfa announcing a reduction in the deposit benchmark interest rates, with the highest fixed deposit rate cut by 25 basis points.
①The current banks have started a new round of deposit rate cuts, which is of great significance in maintaining interest margins, thereby ensuring the stable operation of commercial banks and increasing the support for financing the real economy continuously. ②This round of bank deposit rate cuts is expected to basically offset the impact of various loan rate cuts on net interest margins.